Combine mitochondrial-targeted gene therapy and chemotherapy to treat triple-negative breast cancer
Tanvi Varadkar, Zhuoxin Zora Zhou, Jiashuai Zhang, Anusua Sarkar, Zhantao Du, Srijita Chowdhury, Hwayeon Lim, Lufang Zhou, Xiaoguang Margaret Liu · 2025
Read Combine mitochondrial-targeted gene therapy and chemotherapy to treat triple-negative breast cancer by Tanvi Varadkar, Zhuoxin Zora Zhou, Jiashuai Zhang, Anusua Sarkar, Zhantao Du, Srijita Chowdhury, Hwayeon Lim, Lufang Zhou, Xiaoguang Margaret Liu (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12750853.txt.
Description
Tanvi Varadkar and co-authors combine a mitochondria-targeting gene therapy with a standard drug class against triple-negative breast cancer, an aggressive subtype that resists chemotherapy and often returns. Their light-based technology parks inside mitochondria, collapses the voltage across the mitochondrial membrane, and kills the cancer cell from within. A targeted virus, guided by an antibody that homes to these tumors, delivers the therapy.
Cell studies confirmed the therapy entered tumors and switched on, and pairing it with PARP inhibitor drugs killed far more cells. In four mouse models, including patient-derived tumors, the combination shrank tumor burden by ninety-five to one hundred percent and blocked spread. Treated tumors showed collapsed mitochondria, stalled DNA copying, and immune cells moving in.
Catalog record
| CREATOR | Tanvi Varadkar, Zhuoxin Zora Zhou, Jiashuai Zhang, Anusua Sarkar, Zhantao Du, Srijita Chowdhury, Hwayeon Lim, Lufang Zhou, Xiaoguang Margaret Liu |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 63 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |